Last reviewed · How we verify
PP1M
PP1M is a phosphodiesterase 10 (PDE10) inhibitor that increases intracellular cyclic nucleotide levels to modulate neuronal signaling.
PP1M is a phosphodiesterase 10 (PDE10) inhibitor that increases intracellular cyclic nucleotide levels to modulate neuronal signaling. Used for Schizophrenia.
At a glance
| Generic name | PP1M |
|---|---|
| Also known as | R092670 |
| Sponsor | Janssen Research & Development, LLC |
| Drug class | PDE10 inhibitor |
| Target | PDE10A |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | Phase 3 |
Mechanism of action
PDE10 inhibitors block the breakdown of cyclic AMP and cyclic GMP in neurons, leading to enhanced signaling through these second messenger pathways. This mechanism is thought to restore balance in striatal medium spiny neuron activity and may have therapeutic effects in neuropsychiatric and neurodegenerative conditions. The drug is being developed for central nervous system indications where PDE10 inhibition may provide clinical benefit.
Approved indications
- Schizophrenia
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia (NA)
- Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia (PHASE4)
- A Study of Paliperidone Palmitate 6-Month Formulation (PHASE3)
- A Study of Paliperidone Palmitate 6-Month Formulation (PHASE3)
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities (PHASE4)
- A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
- A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PP1M CI brief — competitive landscape report
- PP1M updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI